Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 925302, 21 pages
http://dx.doi.org/10.1155/2014/925302
Review Article

A Review on the Traditional Chinese Medicinal Herbs and Formulae with Hypolipidemic Effect

1Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong
2State Key Laboratory of Chinese Medicine and Molecular Pharmacology (Incubation), Shenzhen 518057, China
3Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
4Xuhui District Central Hospital of Shanghai, Shanghai 200031, China
5Food Safety and Technology Research Centre, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong

Received 28 February 2014; Revised 4 May 2014; Accepted 10 May 2014; Published 7 July 2014

Academic Editor: Sharad S. Singhal

Copyright © 2014 Tung-Ting Sham et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. G. Athyros, K. Tziomalos, A. Karagiannis, and D. P. Mikhailidis, “Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment,” The Open Cardiovascular Medicine Journal, vol. 5, pp. 24–34, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. P. K. Shah, S. Kaul, J. Nilsson, and B. Cercek, “Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I,” Circulation, vol. 104, no. 19, pp. 2376–2383, 2001. View at Google Scholar · View at Scopus
  3. P. Durrington, “Dyslipidaemia,” The Lancet, vol. 362, no. 9385, pp. 717–731, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. A. S. Go, D. Mozaffarian, V. L. Roger et al., “Heart disease and stroke statistics-2013 update: a Report from the American Heart Association,” Circulation, vol. 127, no. 1, p. e6-e245, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. D. M. Kusters, H. J. Avis, M. J. Braamskamp et al., “Inheritance pattern of familial hypercholesterolemia and markers of cardiovascular risk,” Journal of Lipid Research, vol. 54, no. 9, pp. 2543–2549, 2013. View at Google Scholar
  6. P. J. Talmud, S. Shah, R. Whittall et al., “Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study,” The Lancet, vol. 381, no. 9874, pp. 1293–1301, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. J. L. Goldstein, H. G. Schrott, W. R. Hazzard, E. L. Bierman, and A. G. Motulsky, “Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia,” The Journal of Clinical Investigation, vol. 52, no. 7, pp. 1544–1568, 1973. View at Google Scholar · View at Scopus
  8. D. S. Fredrickson, R. I. Levy, and R. S. Lees, “Fat transport in lipoproteins—an integrated approach to mechanisms and disorders,” The New England Journal of Medicine, vol. 276, no. 1, pp. 34–42, 1967. View at Google Scholar · View at Scopus
  9. T. T. Hlaing and A. Park, “Hyperlipidaemia,” Medicine, vol. 41, no. 10, pp. 607–609, 2013. View at Google Scholar
  10. S. P. Mahamuni, R. D. Khose, F. Menaa, and S. L. Badole, “Therapeutic approaches to drug targets in hyperlipidemia,” BioMedicine, vol. 2, no. 4, pp. 137–146, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. P. R. Deepa and P. Varalakshmi, “Atheroprotective effect of exogenous heparin-derivative treatment on the aortic disturbances and lipoprotein oxidation in hypercholesterolemic diet fed rats,” Clinica Chimica Acta, vol. 355, no. 1-2, pp. 119–130, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. C. D. Mathers and D. Loncar, “Projections of global mortality and burden of disease from 2002 to 2030,” PLoS Medicine, vol. 3, no. 11, article e442, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. G. A. Roth, S. D. Fihn, A. H. Mokdad, W. Aekplakorn, T. Hasegawa, and S. S. Lim, “High total serum cholesterol, medication coverage and therapeutic control: an analysis of national health examination survey data from eight countries,” Bulletin of the World Health Organization, vol. 89, no. 2, pp. 92–101, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. P. P. Toth, “Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugs,” Drugs, vol. 70, no. 11, pp. 1363–1379, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. A. M. Gotto, “Cholesterol management in theory and practice,” Circulation, vol. 96, no. 12, pp. 4424–4430, 1997. View at Google Scholar
  16. W. Xie, Y. Zhao, and L. Du, “Emerging approaches of traditional Chinese medicine formulas for the treatment of hyperlipidemia,” Journal of Ethnopharmacology, vol. 140, no. 2, pp. 345–367, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. M. M. Hussain, “Intestinal lipid absorption and lipoprotein formation,” Current Opinion in Lipidology, vol. 25, no. 3, pp. 200–206, 2014. View at Publisher · View at Google Scholar
  18. A. J. Lusis and P. Pajukanta, “A treasure trove for lipoprotein biology,” Nature Genetics, vol. 40, no. 2, pp. 129–130, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Stein and O. Stein, “The Origin and Fate of LDL,” in Atherosclerosis, G. Manning and M. D. Haust, Eds., pp. 413–420, Springer, New York, NY, USA, 1977. View at Google Scholar
  20. C. J. Fielding and P. E. Fielding, “Molecular physiology of reverse cholesterol transport,” Journal of Lipid Research, vol. 36, no. 2, pp. 211–228, 1995. View at Google Scholar · View at Scopus
  21. C. Verdier, L. O. Martinez, J. Ferrières et al., “Targeting high-density lipoproteins: update on a promising therapy,” Archives of Cardiovascular Diseases, vol. 106, no. 11, pp. 601–611, 2013. View at Google Scholar
  22. N. Y. Kalaany and D. J. Mangelsdorf, “LXRs and FXR: the Yin and Yang of cholesterol and fat metabolism,” Annual Review of Physiology, vol. 68, no. 1, pp. 159–191, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Deakin, I. Leviev, M. Gomaraschi, L. Calabresi, G. Franceschini, and R. W. James, “Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism,” The Journal of Biological Chemistry, vol. 277, no. 6, pp. 4301–4308, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Kontush, S. Chantepie, and M. J. Chapman, “Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 10, pp. 1881–1888, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Mineo, H. Deguchi, J. H. Griffin, and P. W. Shaul, “Endothelial and antithrombotic actions of HDL,” Circulation Research, vol. 98, no. 11, pp. 1352–1364, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. B. J. Ansell, M. Navab, S. Hama et al., “Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment,” Circulation, vol. 108, no. 22, pp. 2751–2756, 2003. View at Google Scholar
  27. J. Bernard, “Free fatty acid receptor family: novel targets for the treatment of diabetes and dyslipidemia,” Current Opinion in Investigational Drugs, vol. 9, no. 10, pp. 1078–1083, 2008. View at Google Scholar · View at Scopus
  28. M. A. Micallef and M. L. Garg, “Beyond blood lipids: phytosterols, statins and omega-3 polyunsaturated fatty acid therapy for hyperlipidemia,” The Journal of Nutritional Biochemistry, vol. 20, no. 12, pp. 927–939, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Funatsu, K. Suzuki, M. Goto et al., “Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells,” Atherosclerosis, vol. 157, no. 1, pp. 107–115, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. P. O. Kwiterovich Jr., “Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity,” American Journal of Cardiology, vol. 90, no. 8, pp. 30–47, 2002. View at Google Scholar · View at Scopus
  31. L. Mabile, O. Meilhac, I. Escargueil-Blanc et al., “Mitochondrial function is involved in LDL oxidation mediated by human cultured endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 8, pp. 1575–1582, 1997. View at Google Scholar
  32. M. K. Cathcart, D. W. Morel, and G. M. Chisolm III, “Monocytes and neutrophils oxidize low density lipoprotein making it cytotoxic,” Journal of Leukocyte Biology, vol. 38, no. 2, pp. 341–350, 1985. View at Google Scholar · View at Scopus
  33. R. Ross, “The pathogenesis of atherosclerosis: a perspective for the 1990s,” Nature, vol. 362, no. 6423, pp. 801–809, 1993. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Blanco-Molina, D. Martín-Escalante, D. Bravo et al., “High-density lipoproteins protect endothelial cells from apoptosis induced by oxidized low-density lipoproteins,” Protoplasma, vol. 211, no. 3-4, pp. 198–206, 2000. View at Google Scholar · View at Scopus
  35. M. Jacobs, F. Plane, and K. R. Bruckdorfer, “Native and oxidized low-density lipoproteins have different inhibitory effects on endothelium-derived relaxing factor in the rabbit aorta,” British Journal of Pharmacology, vol. 100, no. 1, pp. 21–26, 1990. View at Google Scholar · View at Scopus
  36. H. Chan, M. Lougheed, I. Laher, and U. P. Steinbrecher, “Oxidized low-density lipoprotein inhibits endothelium-dependent vasodilation by an antioxidant-sensitive, lysophosphatidylcholine-independent mechanism,” Journal of Cardiovascular Pharmacology, vol. 41, no. 6, pp. 856–865, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. C. P. Sparrow, S. Parthasarathy, and D. Steinberg, “A macrophage receptor that recognizes oxidized low density lipoprotein but not acetylated low density lipoprotein,” The Journal of Biological Chemistry, vol. 264, no. 5, pp. 2599–2604, 1989. View at Google Scholar · View at Scopus
  38. T. Gordon and W. B. Kannel, “Premature mortality from coronary heart disease. The Framingham study,” The Journal of the American Medical Association, vol. 215, no. 10, pp. 1617–1625, 1971. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Holvoet, N. S. Jenny, P. J. Schreiner, R. P. Tracy, and D. R. Jacobs, “The relationship between oxidized LDL and other cardiovascular risk factors and subclinical CVD in different ethnic groups: the Multi-Ethnic Study of Atherosclerosis (MESA),” Atherosclerosis, vol. 194, no. 1, pp. 245–252, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. J. D. Brown and J. Plutzky, “Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets,” Circulation, vol. 115, no. 4, pp. 518–533, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. B. Staels, J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, and J.-C. Fruchart, “Mechanism of action of fibrates on lipid and lipoprotein metabolism,” Circulation, vol. 98, no. 19, pp. 2088–2093, 1998. View at Google Scholar · View at Scopus
  42. T. Sudhop, D. Lütjohann, A. Kodal et al., “Inhibition of intestinal cholesterol absorption by ezetimibe in humans,” Circulation, vol. 106, no. 15, pp. 1943–1948, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. M. H. Davidson, “A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia,” Journal of Clinical Lipidology, vol. 5, no. 2, pp. 76–81, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. G. L. Vega, N. B. Cater, S. Meguro, and S. M. Grundy, “Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia,” American Journal of Cardiology, vol. 95, no. 11, pp. 1309–1313, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. C. S. Vaccari, R. A. Hammoud, S. H. Nagamia, K. Ramasamy, A. L. Dollar, and B. V. Khan, “Revisiting niacin: reviewing the evidence,” Journal of Clinical Lipidology, vol. 1, no. 4, pp. 248–255, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. A. C. Rustan, J. O. Nossen, E. N. Christiansen, and C. A. Drevon, “Eicosapentaenoic acid reduces hepatic synthesis and secretion of triacylglycerol by decreasing the activity of acyl-coenzyme A:1,2-diacylglycerol acyltransferase,” Journal of Lipid Research, vol. 29, no. 11, pp. 1417–1426, 1988. View at Google Scholar · View at Scopus
  47. J. S. Parks, F. L. Johnson, M. D. Wilson, and L. L. Rudel, “Effect of fish oil diet on hepatic lipid metabolism in nonhuman primates: lowering of secretion of hepatic triglyceride but not apoB,” Journal of Lipid Research, vol. 31, no. 3, pp. 455–466, 1990. View at Google Scholar · View at Scopus
  48. W. S. Harris, M. Miller, A. P. Tighe, M. H. Davidson, and E. J. Schaefer, “Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives,” Atherosclerosis, vol. 197, no. 1, pp. 12–24, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. R. Hou and A. C. Goldberg, “Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety,” Endocrinology and Metabolism Clinics of North America, vol. 38, no. 1, pp. 79–97, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. P. Kardas, “Prevalence and reasons for non-adherence to hyperlipidemia treatment,” Central European Journal of Medicine, vol. 8, no. 5, pp. 539–547, 2013. View at Google Scholar
  51. P. H. Langsjoen, J. O. Langsjoen, A. M. Langsjoen, and L. A. Lucas, “Treatment of statin adverse effects with supplemental Coenzyme Q 10 and statin drug discontinuation,” BioFactors, vol. 25, no. 1–4, pp. 147–152, 2005. View at Google Scholar · View at Scopus
  52. D. Rozman and K. Monostory, “Perspectives of the non-statin hypolipidemic agents,” Pharmacology and Therapeutics, vol. 127, no. 1, pp. 19–40, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. X. B. Dou, X. D. Wo, and C. L. Fan, “Progress of research in treatment of hyperlipidemia by monomer or compound recipe of Chinese herbal medicine,” Chinese Journal of Integrative Medicine, vol. 14, no. 1, pp. 71–75, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. Chinese Pharmacopoeia Commission, Pharmacopoeia of the People's Republic of China, Chinese Medical Science Press, Beijing, China, 2010.
  55. W. B. Qian, H. Pang, D. Q. Xie, L. Y. Xi, and H. Y. Zhang, “Preparation and research into the effects on the decrease of the hyperlipidemica of mice of water and alcohol extracts of Alisma orientalis,” Journal of Mathematical Medicine, vol. 20, no. 6, pp. 836–838, 2007. View at Google Scholar
  56. X. Y. Yu, J. H. Zhong, and X. Zhang, “Hypolipidemic effects and its chemical principles of Ze Xie,” Chinese Medicine Modern Distance Education of China, vol. 8, no. 11, p. 250, 2010. View at Google Scholar
  57. H. Dan, J. Wu, M. Peng et al., “Hypolipidemic effects of Alismatis Rhizome on lipid profile in mice fed high-fat diet,” Saudi Medical Journal, vol. 32, no. 7, pp. 701–707, 2011. View at Google Scholar · View at Scopus
  58. X. Hong, H. Tang, L. Wu, and A. Li, “Protective effects of the Alisma orientalis extract on the experimental nonalcoholic fatty liver disease,” Journal of Pharmacy and Pharmacology, vol. 58, no. 10, pp. 1391–1398, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. Y. Imai, H. Matsumura, and Y. Aramaki, “Hypocholesterolemic effect of alisol A-24-monoacetate and its related compounds in rats,” The Japanese Journal of Pharmacology, vol. 20, no. 2, pp. 222–228, 1970. View at Google Scholar · View at Scopus
  60. M. Q. Huang, W. Xu, S. S. Wu, J. J. Lu, and X. P. Chen, “A 90-day subchronic oral toxicity study of triterpene-enriched extract from Alismatis Rhizoma in rats,” Food and Chemical Toxicology, vol. 58, pp. 318–323, 2013. View at Google Scholar
  61. M. F. Yuen, S. Tam, J. Fung, D. K. H. Wong, B. C. Y. Wong, and C. L. Lai, “Traditional Chinese medicine causing hepatotoxicity in patients with chronic hepatitis B infection: a 1-year prospective study,” Alimentary Pharmacology and Therapeutics, vol. 24, no. 8, pp. 1179–1186, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. X. Zhao, L. Lu, Y. Zhang, and B. Zhang, “Study on discriminating nephrotoxic components in Zexie,” China Journal of Chinese Materia Medica, vol. 36, no. 6, pp. 758–761, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. T. Yokozawa, A. Ishida, E. J. Cho, and T. Nakagawa, “The effects of Coptidis Rhizoma extract on a hypercholesterolemic animal model,” Phytomedicine, vol. 10, no. 1, pp. 17–22, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. Cao, W. Bei, Y. Hu et al., “Hypocholesterolemia of Rhizoma Coptidis alkaloids is related to the bile acid by up-regulated CYP7A1 in hyperlipidemic rats,” Phytomedicine, vol. 19, no. 8-9, pp. 686–692, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. W. Xie, D. Gu, J. Li, K. Cui, and Y. Zhang, “Effects and action mechanisms of berberine and Rhizoma Coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice,” PLoS ONE, vol. 6, no. 9, Article ID e24520, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. W. Kong, J. Wei, P. Abidi et al., “Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins,” Nature Medicine, vol. 10, no. 12, pp. 1344–1351, 2004. View at Publisher · View at Google Scholar · View at Scopus
  67. Y. Hu, E. A. Ehli, J. Kittelsrud et al., “Lipid-lowering effect of berberine in human subjects and rats,” Phytomedicine, vol. 19, no. 10, pp. 861–867, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. W. J. Kong, J. Wei, Z. Y. Zuo et al., “Combination of simvastatin with berberine improves the lipid-lowering efficacy,” Metabolism: Clinical and Experimental, vol. 57, no. 8, pp. 1029–1037, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. D. H. Kuo, C. H. Yeh, P. C. Shieh, K. C. Cheng, F. A. Chen, and J. T. Cheng, “Effect of ShanZha, a Chinese herbal product, on obesity and dyslipidemia in hamsters receiving high-fat diet,” Journal of Ethnopharmacology, vol. 124, no. 3, pp. 544–550, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. J. Y. Zhang, R. X. Liang, L. Wang et al., “Effects of an aqueous extract of Crataegus pinnatifida Bge. var. major NEBr. fruit on experimental atherosclerosis in rats,” Journal of Ethnopharmacology, vol. 148, no. 2, pp. 563–569, 2013. View at Google Scholar
  71. Y. Lin, M. A. Vermeer, and E. A. Trautwein, “Triterpenic acids present in hawthorn lower plasma cholesterol by inhibiting intestinal ACAT activity in hamsters,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 801272, 9 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. C. Y. Kwok, C. N. Y. Wong, M. Y. C. Yau et al., “Consumption of dried fruit of Crataegus pinnatifida (hawthorn) suppresses high-cholesterol diet-induced hypercholesterolemia in rats,” Journal of Functional Foods, vol. 2, no. 3, pp. 179–186, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. M. H. Pittler, K. Schmidt, and E. Ernst, “Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials,” The American Journal of Medicine, vol. 114, no. 8, pp. 665–674, 2003. View at Publisher · View at Google Scholar · View at Scopus
  74. M. H. Pittler, R. Guo, and E. Ernst, “Hawthorn extract for treating chronic heart failure,” Cochrane Database of Systematic Reviews, no. 1, p. CD005312, 2008. View at Google Scholar · View at Scopus
  75. C. Daniele, G. Mazzanti, M. H. Pittler, and E. Ernst, “Adverse-event profile of Crataegus spp.: a systematic review,” Drug Safety, vol. 29, no. 6, pp. 523–535, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. S. H. Kim and K. S. Park, “Effects of Panax ginseng extract on lipid metabolism in humans,” Pharmacological Research, vol. 48, no. 5, pp. 511–513, 2003. View at Publisher · View at Google Scholar · View at Scopus
  77. D. H. M. El-Farok and E. S. El-Denshry, “Lipid lowering effect of ginseng and alpha-lipoic acid in hypercholesterolemic patients,” Global Journal of Pharmacology, vol. 7, no. 3, pp. 298–306, 2013. View at Google Scholar
  78. M. Inoue, C. Z. Wu, D. Q. Dou, Y. J. Chen, and Y. Ogihara, “Lipoprotein lipase activation by red Ginseng saponins in hyperlipidemia model animals,” Phytomedicine, vol. 6, no. 4, pp. 257–265, 1999. View at Google Scholar · View at Scopus
  79. S. Y. Hwang, D. J. Son, I. W. Kim et al., “Korean red ginseng attenuates hypercholesterolemia-enhanced platelet aggregation through suppression of diacylglycerol liberation in high-cholesterol-diet-fed rabbits,” Phytotherapy Research, vol. 22, no. 6, pp. 778–783, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Lim, J. W. Yoon, S. H. Choi et al., “Effect of ginsam, a vinegar extract from Panax ginseng, on body weight and glucose homeostasis in an obese insulin-resistant rat model,” Metabolism: Clinical and Experimental, vol. 58, no. 1, pp. 8–15, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. Y. S. Kwak, J. S. Kyung, J. S. Kim, J. Y. Cho, and M. H. Rhee, “Anti-hyperlipidemic effects of red ginseng acidic polysaccharide from Korean red ginseng,” Biological and Pharmaceutical Bulletin, vol. 33, no. 3, pp. 468–472, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. N. Karu, R. Reifen, and Z. Kerem, “Weight gain reduction in mice fed Panax ginseng saponin, a pancreatic lipase inhibitor,” Journal of Agricultural and Food Chemistry, vol. 55, no. 8, pp. 2824–2828, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. L. S. Lee, C. W. Cho, H. D. Hong et al., “Hypolipidemic and antioxidant properties of phenolic compound-rich extracts from white ginseng (Panax ginseng) in cholesterol-fed rabbits,” Molecules, vol. 18, no. 10, pp. 12548–12560, 2013. View at Google Scholar
  84. H. L. Jung and H. Y. Kang, “Effects of Korean red ginseng supplementation on muscle glucose uptake in high-fat fed rats,” Chinese Journal of Natural Medicines, vol. 11, no. 5, pp. 494–499, 2013. View at Google Scholar
  85. N. Lin, D. L. Cai, D. Jin, Y. Chen, and J. J. Shi, “Ginseng panaxoside Rb1 reduces body weight in diet-induced obese mice,” Cell Biochemistry and Biophysics, vol. 68, no. 1, pp. 189–194, 2014. View at Google Scholar
  86. S. Lee, M. S. Lee, C. T. Kim, I. H. Kim, and Y. Kim, “Ginsenoside RG3 reduces lipid accumulation with AMP-activated protein kinase (AMPK) activation in HepG2 cells,” International Journal of Molecular Sciences, vol. 13, no. 5, pp. 5729–5739, 2012. View at Publisher · View at Google Scholar · View at Scopus
  87. H. G. Kim, S. R. Yoo, H. J. Park et al., “Antioxidant effects of Panax ginseng C.A. Meyer in healthy subjects: a randomized, placebo-controlled clinical trial,” Food and Chemical Toxicology, vol. 49, no. 9, pp. 2229–2235, 2011. View at Publisher · View at Google Scholar · View at Scopus
  88. J. S. Oh, S. R. Lee, K. T. Hwang, and G. E. Ji, “The anti-obesity effects of the dietary combination of fermented red ginseng with levan in high fat diet mouse model,” Phytotherapy Research, vol. 28, no. 4, pp. 617–622, 2014. View at Google Scholar
  89. N. H. Lee and C. G. Son, “Systematic review of randomized controlled trials evaluating the efficacy and safety of ginseng,” Journal of Acupuncture and Meridian Studies, vol. 4, no. 2, pp. 85–97, 2011. View at Publisher · View at Google Scholar · View at Scopus
  90. R. K. Siegel, “Ginseng abuse syndrome. Problems with the panacea,” Journal of the American Medical Association, vol. 241, no. 15, pp. 1614–1615, 1979. View at Publisher · View at Google Scholar · View at Scopus
  91. B. D. Jones and A. M. Runikis, “Interaction of ginseng with phenelzine,” Journal of Clinical Psychopharmacology, vol. 7, no. 3, pp. 201–202, 1987. View at Google Scholar · View at Scopus
  92. S. H. Lee, Y. M. Ahn, S. Y. Ahn, H. K. Doo, and B. C. Lee, “Interaction between warfarin and Panax ginseng in ischemic stroke patients,” Journal of Alternative and Complementary Medicine, vol. 14, no. 6, pp. 715–721, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. H. H. Tsai, H. W. Lin, Y. H. Lu, Y. L. Chen, and G. B. Mahady, “A review of potential harmful interactions between anticoagulant/antiplatelet agents and Chinese herbal medicines,” PLoS ONE, vol. 8, no. 5, Article ID e64255, 2013. View at Publisher · View at Google Scholar · View at Scopus
  94. State Administration of Traditional Chinese Medicine, Chinese Materia Medica (Zhonghua Bencao in Chinese), Shanghai Scientific and Technical Publishers, Shanghai, China, 1998.
  95. W. Xia, C. Sun, Y. Zhao, and L. Wu, “Hypolipidemic and antioxidant activities of Sanchi (Radix Notoginseng) in rats fed with a high fat diet,” Phytomedicine, vol. 18, no. 6, pp. 516–520, 2011. View at Publisher · View at Google Scholar · View at Scopus
  96. J. H. Wu, G. P. H. Leung, Y. W. Kwan et al., “Suppression of diet-induced hypercholesterolaemia by saponins from Panax notoginseng in rats,” Journal of Functional Foods, vol. 5, no. 3, pp. 1159–1169, 2013. View at Publisher · View at Google Scholar · View at Scopus
  97. Y. G. Zhang, H. G. Zhang, G. Y. Zhang et al., “Panax notoginseng saponins attenuate atherosclerosis in rats by regulating the blood lipid profile and an anti-inflammatory action,” Clinical and Experimental Pharmacology and Physiology, vol. 35, no. 10, pp. 1238–1244, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. W. Ji and B. Q. Gong, “Hypolipidemic effects and mechanisms of Panax notoginseng on lipid profile in hyperlipidemic rats,” Journal of Ethnopharmacology, vol. 113, no. 2, pp. 318–324, 2007. View at Publisher · View at Google Scholar · View at Scopus
  99. A. F. G. Cicero, G. Vitale, G. Savino, and R. Arletti, “Panax notoginseng (Burk.) Effects on fibrinogen and lipid plasma level in rats fed on a high-fat diet,” Phytotherapy Research, vol. 17, no. 2, pp. 174–178, 2003. View at Publisher · View at Google Scholar · View at Scopus
  100. H. Sinzinger and M. Rodrigues, “Atorvastatin and fibrinogen—a small subgroup shows extreme response,” Atherosclerosis, vol. 145, no. 2, pp. 415–417, 1999. View at Publisher · View at Google Scholar · View at Scopus
  101. A. S. Wierzbicki, P. J. Lumb, Y. K. Semra, and M. A. Crook, “Effect of atorvastatin on plasma fibrinogen,” The Lancet, vol. 351, no. 9102, pp. 569–570, 1998. View at Publisher · View at Google Scholar · View at Scopus
  102. Y. Chen, Y. Li, and G. Zhu, “Analysis of 103 cases with adverse drug reactions induced by sanqizongzaogan injection,” China Journal of Chinese Materia Medica, vol. 35, no. 2, pp. 237–239, 2010. View at Publisher · View at Google Scholar · View at Scopus
  103. G. Wang, L. Wang, Z. Y. Xiong, B. Mao, and T. Q. Li, “Compound salvia pellet, a traditional Chinese medicine, for the treatment of chronic stable angina pectoris compared with nitrates: a meta-analysis,” Medical Science Monitor, vol. 12, no. 1, pp. SR1–SR7, 2006. View at Google Scholar · View at Scopus
  104. J. Ma, Y. Li, Q. Ye et al., “Constituents of red yeast rice, a traditional Chinese food and medicine,” Journal of Agricultural and Food Chemistry, vol. 48, no. 11, pp. 5220–5225, 2000. View at Publisher · View at Google Scholar · View at Scopus
  105. L. Childress, A. Gay, A. Zargar, and M. K. Ito, “Review of red yeast rice content and current Food and Drug Administration oversight,” Journal of Clinical Lipidology, vol. 7, no. 2, pp. 117–122, 2013. View at Publisher · View at Google Scholar · View at Scopus
  106. M. Journoud and P. J. H. Jones, “Red yeast rice: a new hypolipidemic drug,” Life Sciences, vol. 74, no. 22, pp. 2675–2683, 2004. View at Publisher · View at Google Scholar · View at Scopus
  107. O. Gheith, H. Sheashaa, M. Abdelsalam, Z. Shoeir, and M. Sobh, “Efficacy and safety of Monascus purpureus Went rice in children and young adults with secondary hyperlipidemia: a preliminary report,” European Journal of Internal Medicine, vol. 20, no. 3, pp. e57–e61, 2009. View at Publisher · View at Google Scholar · View at Scopus
  108. C. W. Yang and S. A. Mousa, “The effect of red yeast rice (Monascus purpureus) in dyslipidemia and other disorders,” Complementary Therapies in Medicine, vol. 20, no. 6, pp. 466–474, 2012. View at Publisher · View at Google Scholar · View at Scopus
  109. W. Wei, C. Li, Y. Wang, H. Su, J. Zhu, and D. Kritchevsky, “Hypolipidemic and anti-atherogenic effects of long-term Cholestin (Monascus purpureus-fermented rice, red yeast rice) in cholesterol fed rabbits,” The Journal of Nutritional Biochemistry, vol. 14, no. 6, pp. 314–318, 2003. View at Publisher · View at Google Scholar · View at Scopus
  110. M. P. Bogsrud, L. Ose, G. Langslet et al., “HypoCol (red yeast rice) lowers plasma cholesterol—a randomized placebo controlled study,” Scandinavian Cardiovascular Journal, vol. 44, no. 4, pp. 197–200, 2010. View at Publisher · View at Google Scholar · View at Scopus
  111. J. Liu, J. Zhang, Y. Shi, S. Grimsgaard, T. Alraek, and V. Fønnebø, “Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials,” Chinese Medicine, vol. 1, article 4, 2006. View at Publisher · View at Google Scholar · View at Scopus
  112. C. D. Liao, Y. C. Chen, H. Y. Lin, L. C. Chiueh, and D. Y. C. Shih, “Incidence of citrinin in red yeast rice and various commercial Monascus products in Taiwan from 2009 to 2012,” Food Control, vol. 38, pp. 178–183, 2014. View at Google Scholar
  113. L. P. Yan, S. W. Chan, A. S. C. Chan, S. L. Chen, X. J. Ma, and H. X. Xu, “Puerarin decreases serum total cholesterol and enhances thoracic aorta endothelial nitric oxide synthase expression in diet-induced hypercholesterolemic rats,” Life Sciences, vol. 79, no. 4, pp. 324–330, 2006. View at Publisher · View at Google Scholar · View at Scopus
  114. D. W. Lim, J. G. Kim, and Y. T. Kim, “Effects of dietary isoflavones from Puerariae Radix on lipid and bone metabolism in ovariectomized rats,” Nutrients, vol. 5, no. 7, pp. 2734–2746, 2013. View at Google Scholar
  115. N. Peng, J. K. Prasain, Y. Dai et al., “Chronic dietary kudzu isoflavones improve components of metabolic syndrome in stroke-prone spontaneously hypertensive rats,” Journal of Agricultural and Food Chemistry, vol. 57, no. 16, pp. 7268–7273, 2009. View at Publisher · View at Google Scholar · View at Scopus
  116. J. F. Wang, Y. X. Guo, J. Z. Niu, J. Liu, L. Q. Wang, and P. H. Li, “Effects of Radix Puerariae flavones on liver lipid metabolism in ovariectomized rats,” World Journal of Gastroenterology, vol. 10, no. 13, pp. 1967–1970, 2004. View at Google Scholar · View at Scopus
  117. C. T. Wu, J. N. Tzeng, J. N. Lai, S. H. Tsan, and J. D. Wang, “Prescription profile of Chinese herbal products containing coumestrol, genestein, and/or daidzein among female users: an analysis of national health insurance data in Taiwan between 1997 and 2007,” Chinese Medicine, vol. 7, article 22, 2012. View at Publisher · View at Google Scholar · View at Scopus
  118. H. M. Chiang, S. H. Fang, K. C. Wen et al., “Life-threatening interaction between the root extract of Pueraria lobata and methotrexate in rats,” Toxicology and Applied Pharmacology, vol. 209, no. 3, pp. 263–268, 2005. View at Publisher · View at Google Scholar · View at Scopus
  119. Japanese Pharmacopoeia Committee, The Japanese Pharmacopoeia, Society of Japanese Pharmacopoeia, Tokyo, Japan, 15th edition, 2006.
  120. British Pharmacopoeia Commission, British Pharmacopoeia 2009, The Stationery Office on Behalf of the Medicines and Healthcare Products Regulatory Agency, London, UK, 2008.
  121. European Pharmacopoeia Commission, European Pharmacopoeia, European Directorate for the Quality of Medicines and Healthcare of Council of Europe, Strasbourg, France, 7th edition, 2010.
  122. The United States Pharmacopeial Convention, The United States Pharmacopeia/ National Formulary, The United States Pharmacopeial Convention, Rochville, Md, USA, 2009.
  123. Q. Gao, W. S. Qin, Z. H. Jia et al., “Rhein improves renal lesion and ameliorates dyslipidemia in db/db mice with diabetic nephropathy,” Planta Medica, vol. 76, no. 1, pp. 27–33, 2010. View at Publisher · View at Google Scholar · View at Scopus
  124. X. Sheng, M. Wang, M. Lu, B. Xi, H. Sheng, and Y. Q. Zang, “Rhein ameliorates fatty liver disease through negative energy balance, hepatic lipogenic regulation, and immunomodulation in diet-induced obese mice,” American Journal of Physiology: Endocrinology and Metabolism, vol. 300, no. 5, pp. E886–E893, 2011. View at Publisher · View at Google Scholar · View at Scopus
  125. X. Sheng, X. Zhu, Y. Zhang et al., “Rhein protects against obesity and related metabolic disorders through liver X receptor-mediated uncoupling protein 1 upregulation in brown adipose tissue,” International Journal of Biological Sciences, vol. 8, no. 10, pp. 1375–1384, 2012. View at Publisher · View at Google Scholar · View at Scopus
  126. Y. F. Liu, H. M. Yu, C. Zhang et al., “Treatment with rhubarb improves brachial artery endothelial function in patients with atherosclerosis: a randomized, double-blind, placebo-controlled clinical trial,” American Journal of Chinese Medicine, vol. 35, no. 4, pp. 583–595, 2007. View at Publisher · View at Google Scholar · View at Scopus
  127. Y. Liu, F. Yan, Y. Liu et al., “Aqueous extract of rhubarb stabilizes vulnerable atherosclerotic plaques due to depression of inflammation and lipid accumulation,” Phytotherapy Research, vol. 22, no. 7, pp. 935–942, 2008. View at Publisher · View at Google Scholar · View at Scopus
  128. Y. Qin, J. B. Wang, W. J. Kong et al., “The diarrhoeogenic and antidiarrhoeal bidirectional effects of rhubarb and its potential mechanism,” Journal of Ethnopharmacology, vol. 133, no. 3, pp. 1096–1102, 2011. View at Publisher · View at Google Scholar · View at Scopus
  129. W. H. Organisation, WHO Monographs on Selected Medicinal Plants, World Health Organisation, Geneva, Switzerland, 1999.
  130. C. M. Li, X. L. Dong, X. D. Fan et al., “Aqueous extract of danshen (Salvia miltiorrhiza Bunge) protects ovariectomized rats fed with high-fat diet from endothelial dysfunction,” Menopause, vol. 20, no. 1, pp. 100–109, 2013. View at Publisher · View at Google Scholar · View at Scopus
  131. S. Wassmann, A. T. Bäumer, K. Strehlow et al., “Endothelial dysfunction and oxidative stress during estrogen deficiency in spontaneously hypertensive rats,” Circulation, vol. 103, no. 3, pp. 435–441, 2001. View at Google Scholar · View at Scopus
  132. Y. L. Chen, S. P. Yang, M. S. Shiao, J. W. Chen, and S. J. Lin, “Salvia miltiorrhiza inhibits intimal hyperplasia and monocyte chemotactic protein-1 expression after balloon injury in cholesterol-fed rabbits,” Journal of Cellular Biochemistry, vol. 83, no. 3, pp. 484–493, 2001. View at Publisher · View at Google Scholar · View at Scopus
  133. Y. J. Wu, C. Y. Hong, S. J. Lin, P. Wu, and M. S. Shiao, “Increase of vitamin E content in LDL and reduction of atherosclerosis in cholesterol-fed rabbits by a water-soluble antioxidant-rich fraction of Salvia miltiorrhiza,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 3, pp. 481–486, 1998. View at Google Scholar · View at Scopus
  134. W. Ji and B. Q. Gong, “Hypolipidemic activity and mechanism of purified herbal extract of Salvia miltiorrhiza in hyperlipidemic rats,” Journal of Ethnopharmacology, vol. 119, no. 2, pp. 291–298, 2008. View at Publisher · View at Google Scholar · View at Scopus
  135. M. Wang, J. Liu, B. Zhou et al., “Acute and sub-chronic toxicity studies of Danshen injection in Sprague-Dawley rats,” Journal of Ethnopharmacology, vol. 141, no. 1, pp. 96–103, 2012. View at Publisher · View at Google Scholar · View at Scopus
  136. K. Chan, A. C. T. Lo, J. H. K. Yeung, and K. S. Woo, “The effects of Danshen (Salvia miltiorrhiza) on warfarin pharmacodynamics and pharmacokinetics of warfarin enantiomers in rats,” Journal of Pharmacy and Pharmacology, vol. 47, no. 5, pp. 402–406, 1995. View at Google Scholar · View at Scopus
  137. T. Y. K. Chan, “Interaction between warfarin and danshen (Salvia miltiorrhiza),” Annals of Pharmacotherapy, vol. 35, no. 4, pp. 501–504, 2001. View at Google Scholar · View at Scopus
  138. Z. H. Song, Z. N. Ji, C. K. Lo et al., “Chemical and biological assessment of a traditional Chinese herbal decoction prepared from Radix Astragali and Radix Angelicae Sinensis: orthogonal array design to optimize the extraction of chemical constituents,” Planta Medica, vol. 70, no. 12, pp. 1222–1227, 2004. View at Publisher · View at Google Scholar · View at Scopus
  139. H. Zhang, S. Chen, X. Deng, X. Yang, and X. Huang, “The effects of Danggui-Buxue-Tang on blood lipid and expression of genes related to foam cell formation in the early stage of atherosclerosis in diabetic GK rats,” Diabetes Research and Clinical Practice, vol. 77, no. 3, pp. 479–481, 2007. View at Publisher · View at Google Scholar · View at Scopus
  140. Z. W. Lin, L. Y. Zhou, and Q. L. Yi, “Effect of the Danggui Buxue decoction on blood lipid of rats with atherosclerosis,” Clinical Journal of Chinese Medicine, vol. 5, no. 12, pp. 19–20, 2013. View at Google Scholar
  141. Y. Chen, Q. Chen, J. Lu, F. H. Li, Y. Y. Tao, and C. H. Liu, “Effects of Danggui Buxue decoction on lipid peroxidation and MMP-2/9 activities of fibrotic liver in rats,” Chinese Journal of Integrative Medicine, vol. 15, no. 6, pp. 435–441, 2009. View at Publisher · View at Google Scholar · View at Scopus
  142. C. C. Wang, K. F. Cheng, W. M. Lo et al., “A randomized, double-blind, multiple-dose escalation study of a Chinese herbal medicine preparation (Dang Gui Buxue Tang) for moderate to severe menopausal symptoms and quality of life in postmenopausal women,” Menopause, vol. 20, no. 2, pp. 223–231, 2013. View at Publisher · View at Google Scholar · View at Scopus
  143. C. M. Koon, K. S. Woo, P. C. Leung, and K. P. Fung, “Salviae Miltiorrhizae Radix and Puerariae Lobatae Radix herbal formula mediates anti-atherosclerosis by modulating key atherogenic events both in vascular smooth muscle cells and endothelial cells,” Journal of Ethnopharmacology, vol. 138, no. 1, pp. 175–183, 2011. View at Publisher · View at Google Scholar · View at Scopus
  144. C. C. Fong, F. Wei, Y. Chen et al., “Danshen-Gegen decoction exerts proliferative effect on rat cardiac myoblasts H9c2 via MAPK and insulin pathways,” Journal of Ethnopharmacology, vol. 138, no. 1, pp. 60–66, 2011. View at Publisher · View at Google Scholar · View at Scopus
  145. D. Wing-Shing Cheung, C. M. Koon, C. F. Ng et al., “The roots of Salvia miltiorrhiza (Danshen) and Pueraria lobata (Gegen) inhibit atherogenic events: a study of the combination effects of the 2-herb formula,” Journal of Ethnopharmacology, vol. 143, no. 3, pp. 859–866, 2012. View at Publisher · View at Google Scholar · View at Scopus
  146. D. W. S. Cheung, C. M. Koon, E. Wat et al., “A herbal formula containing roots of Salvia miltiorrhiza (Danshen) and Pueraria lobata (Gegen) inhibits inflammatory mediators in LPS-stimulated RAW 264.7 macrophages through inhibition of nuclear factor κb (NFκB) pathway,” Journal of Ethnopharmacology, vol. 145, no. 3, pp. 776–783, 2013. View at Publisher · View at Google Scholar · View at Scopus
  147. D. P. Sieveking, K. S. Woo, K. P. Fung, P. Lundman, S. Nakhla, and D. S. Celermajer, “Chinese herbs Danshen and Gegen modulate key early atherogenic events in vitro,” International Journal of Cardiology, vol. 105, no. 1, pp. 40–45, 2005. View at Publisher · View at Google Scholar · View at Scopus
  148. W. Y. Tam, P. Chook, M. Qiao et al., “The efficacy and tolerability of adjunctive alternative herbal medicine (Salvia miltiorrhiza and Pueraria lobata) on vascular function and structure in coronary patients,” Journal of Alternative and Complementary Medicine, vol. 15, no. 4, pp. 415–421, 2009. View at Publisher · View at Google Scholar · View at Scopus
  149. C. M. Koon, C. H. Ko, X. X. Sun et al., “Gene expression profiling on the molecular action of danshen-gegen formula in a randomized placebo-controlled trial of postmenopausal women with hypercholesterolemia,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 703705, 14 pages, 2013. View at Publisher · View at Google Scholar
  150. L. Zhou, S. Wang, Z. Zhang et al., “Pharmacokinetic and pharmacodynamic interaction of Danshen-Gegen extract with warfarin and aspirin,” Journal of Ethnopharmacology, vol. 143, no. 2, pp. 648–655, 2012. View at Publisher · View at Google Scholar · View at Scopus
  151. J. J. Li, J. T. Li, and J. P. Fu, “Erxian Tang—introduction of a Chinese herbal formula, clinical practice, and experimental studies,” Chinese Journal of Integrative Medicine, vol. 13, no. 1, pp. 67–73, 2007. View at Publisher · View at Google Scholar · View at Scopus
  152. S. C. W. Sze, C. W. Ip, T. B. Ng et al., “Compatibility of multiple herbal components in Erxian Decoction, a Chinese medicinal formula, for treating osteoporosis,” European Journal of Integrative Medicine, vol. 4, no. 2, pp. e187–e196, 2012. View at Publisher · View at Google Scholar · View at Scopus
  153. L. L. D. Zhong, Y. Tong, G. W. K. Tang et al., “A randomized, double-blind, controlled trial of a Chinese herbal formula (Er-Xian decoction) for menopausal symptoms in Hong Kong perimenopausal women,” Menopause, vol. 20, no. 7, pp. 767–776, 2013. View at Publisher · View at Google Scholar · View at Scopus
  154. S. C. W. Sze, H. P. Cheung, T. B. Ng et al., “Effects of Erxian decoction, a Chinese medicinal formulation, on serum lipid profile in a rat model of menopause,” Chinese Medicine, vol. 6, article 40, 2011. View at Publisher · View at Google Scholar · View at Scopus
  155. Y. Yang, J. Qin, B. Ke et al., “Effect of Linguizhugan decoction on hyperlipidemia rats with intermittent fasting,” Journal of Traditional Chinese Medicine, vol. 33, no. 2, pp. 250–252, 2013. View at Google Scholar
  156. D. S. Chen, B. Ke, Y. J. Huang et al., “Effects of the modified Linggui Zhugan Decoction combined with short-term very low calorie diets on glycemic control in newly diagnosed type 2 diabetics,” Journal of Traditional Chinese Medicine, vol. 31, no. 3, pp. 185–188, 2011. View at Google Scholar · View at Scopus
  157. C. Lara-Castro, B. R. Newcomer, J. Rowell et al., “Effects of short-term very low-calorie diet on intramyocellular lipid and insulin sensitivity in nondiabetic and type 2 diabetic subjects,” Metabolism: Clinical and Experimental, vol. 57, no. 1, pp. 1–8, 2008. View at Publisher · View at Google Scholar · View at Scopus
  158. H. R. Lijnen, M. Van Hul, and B. Hemmeryckx, “Caloric restriction improves coagulation and inflammation profile in obese mice,” Thrombosis Research, vol. 129, no. 1, pp. 74–79, 2012. View at Publisher · View at Google Scholar · View at Scopus
  159. Y. Date and K. Kangawa, “Ghrelin as a starvation signal,” Obesity Research and Clinical Practice, vol. 6, no. 4, pp. e263–e269, 2012. View at Publisher · View at Google Scholar · View at Scopus
  160. T. Liu, L. L. Yang, L. Zou et al., “Chinese medicine formula lingguizhugan decoction improves beta-oxidation and metabolism of fatty acid in high-fat-diet-induced rat model of fatty liver disease,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 429738, 9 pages, 2013. View at Publisher · View at Google Scholar
  161. Y. Li, M. Gong, and T. Konishi, “Antioxidant synergism among component herbs of traditional Chinese medicine formula, ShengMai San studied in vitro and in vivo,” Journal of Health Science, vol. 53, no. 6, pp. 692–699, 2007. View at Publisher · View at Google Scholar · View at Scopus
  162. Q. Ni, J. Wang, E. Q. Li et al., “Study on the protective effect of Shengmai San on the myocardium in the type 2 diabetic cardiomyopathy model rat,” Journal of Traditional Chinese Medicine, vol. 31, no. 3, pp. 209–219, 2011. View at Google Scholar · View at Scopus
  163. Y. Z. Zhang, H. Y. Wu, L. W. Ren, H. S. Zhang, X. Jia, and Y. Z. Zhang, “Study on modified Shengmai Yin injection for prevention and treatment of brain impairment in endotoxin shock rats,” Journal of Traditional Chinese Medicine, vol. 30, no. 4, pp. 272–277, 2010. View at Google Scholar · View at Scopus
  164. M. Xu, G. Wang, H. Xie, Q. Huang, W. Wang, and Y. Jia, “Pharmacokinetic comparisons of schizandrin after oral administration of schizandrin monomer, Fructus Schisandrae aqueous extract and Sheng-Mai-San to rats,” Journal of Ethnopharmacology, vol. 115, no. 3, pp. 483–488, 2007. View at Publisher · View at Google Scholar · View at Scopus
  165. L. Cao, Y. Deng, G. Ding, Z. Z. Wang, and W. Xiao, “Effects of Shengmaidan Chewable Tablets on blood lipid and hemorheology in hyperlipedemic model rats,” Drugs & Clinic, vol. 27, no. 3, pp. 214–217, 2012. View at Google Scholar
  166. H. T. Yao, Y. W. Chang, C. T. Chen, M. T. Chiang, L. Chang, and T. K. Yeh, “Shengmai San reduces hepatic lipids and lipid peroxidation in rats fed on a high-cholesterol diet,” Journal of Ethnopharmacology, vol. 116, no. 1, pp. 49–57, 2008. View at Publisher · View at Google Scholar · View at Scopus
  167. J. Wang, X. C. Yang, F. Y. Chu et al., “The effects of Xuefu Zhuyu and Shengmai on the evolution of syndromes and inflammatory markers in patients with unstable angina pectoris after percutaneous coronary intervention: a randomised controlled clinical trial,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 896467, 9 pages, 2013. View at Publisher · View at Google Scholar
  168. Y. C. Zhang, B. J. Lu, M. H. Zhao, Y. Z. Rong, and R. M. Chen, “Effect of Shengmai injection on vascular endothelial and heart functions in patients with coronary heart disease complicated with diabetes mellitus,” Chinese Journal of Integrative Medicine, vol. 14, no. 4, pp. 281–285, 2008. View at Publisher · View at Google Scholar · View at Scopus
  169. C. Y. Chen, L. Y. Lu, P. Chen et al., “Shengmai injection, a traditional Chinese patent medicine, for intradialytic hypotension: a systematic review and meta-analysis,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 703815, 14 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  170. Q. Su and Y. Li, “Interaction between warfarin and the herbal product Shengmai-Yin: a case report of intracerebral hematoma,” Yonsei Medical Journal, vol. 51, no. 5, pp. 793–796, 2010. View at Publisher · View at Google Scholar · View at Scopus
  171. Y. Mu, J. Zhang, S. Zhang et al., “Traditional Chinese medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) activate pregnane X receptor and increase warfarin clearance in rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 316, no. 3, pp. 1369–1377, 2006. View at Publisher · View at Google Scholar · View at Scopus
  172. E. C. H. Yip, A. M. F. Liu, J. T. Y. Wong, and Y. H. Wong, “An aqueous extract of the popular Chinese nutraceutical Kwei Ling Ko (Tortoise shell-Rhizome Jelly) activates the PPARγ pathway and down-regulates the NFκB activity,” Phytomedicine, vol. 12, no. 10, pp. 748–759, 2005. View at Publisher · View at Google Scholar · View at Scopus
  173. J. H. Wu, Q. H. Wang, F. Li et al., “Suppression of diet-induced hypercholesterolemia by turtle jelly, a traditional Chinese functional food, in rats,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 320304, 15 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  174. L. Zhang, L. Zhu, Y. Wang et al., “Characterization and quantification of major constituents of Xue Fu Zhu Yu by UPLC-DAD-MS/MS,” Journal of Pharmaceutical and Biomedical Analysis, vol. 62, pp. 203–209, 2012. View at Publisher · View at Google Scholar · View at Scopus
  175. J. J. Lee, W. H. Hsu, T. L. Yen et al., “Traditional Chinese medicine, Xue-Fu-Zhu-Yu decoction, potentiates tissue plasminogen activator against thromboembolic stroke in rats,” Journal of Ethnopharmacology, vol. 134, no. 3, pp. 824–830, 2011. View at Publisher · View at Google Scholar · View at Scopus
  176. F. Y. Chu, J. Wang, K. W. Yao, and Z. Z. Li, “Effect of Xuefu Zhuyu Capsule on the symptoms and signs and health-related quality of life in the unstable angina patients with blood-stasis syndrome after percutaneous coronary intervention: a randomized controlled trial,” Chinese Journal of Integrative Medicine, vol. 16, no. 5, pp. 399–405, 2010. View at Publisher · View at Google Scholar · View at Scopus
  177. X. M. Yu, G. H. Yang, and P. Li, “Mechanism of lowering blood lipids of Xuefuzhuyu decoction in patients with hyperlipidemia,” Liaoning Journal of Traditional Chinese Medicine, vol. 2, pp. 289–291, 2014. View at Google Scholar
  178. C. Dong, W. Huang, Z. H. Geng, and S. Gao, “Effects of Xuefu Zhyyu decoction on intercellular adhesion molecule and lipid peroxidation of experimental atherosclerosis rats,” Journal of Hebei University (Natural Science Edition), vol. 32, no. 6, pp. 650–654, 2012. View at Google Scholar
  179. Z. H. Geng, B. D. Shou, H. Liu, Y. B. Yang, and J. J. Ren, “Effect of Xuefu Zhuyu decoction on the expression of blood-lipid and vasoactive substances in the rats with atherosclerosis,” Journal of Hebei University (Natural Science Edition), vol. 31, no. 3, pp. 304–308, 2011. View at Google Scholar
  180. D. Y. Yu, K. B. Wei, and X. D. Wo, “Clinical and experimental study of Xuefu Zhuyu Tang in treating Qi stagnation and the blood stasis type of hyperlipidemia,” Chinese Journal of Modern Developments in Traditional Medicine, vol. 8, no. 10, pp. 601–603, 1988. View at Google Scholar · View at Scopus
  181. X. Song, J. Wang, P. Wang, N. Tian, M. Yang, and L. Kong, “1H NMR-based metabolomics approach to evaluate the effect of Xue-Fu-Zhu-Yu decoction on hyperlipidemia rats induced by high-fat diet,” Journal of Pharmaceutical and Biomedical Analysis, vol. 78-79, pp. 202–210, 2013. View at Publisher · View at Google Scholar · View at Scopus
  182. L. Liu, Y. Cheng, and H. Zhang, “Phytochemical analysis of anti-atherogenic constituents of Xue-Fu-Zhu-Yu-Tang using HPLC-DAD-ESI-MS,” Chemical and Pharmaceutical Bulletin, vol. 52, no. 11, pp. 1295–1301, 2004. View at Publisher · View at Google Scholar · View at Scopus
  183. M. R. Wang and M. X. Han, “Advances in researches on visceral pathogenesis of hyperlipidemia,” Chinese Journal of Basic Medicine in Traditional Chinese Medicine, vol. 11, no. 4, pp. 316–319, 2005. View at Google Scholar
  184. Y. J. Wu, Z. Wang, and Y. F. Wang, “A brief study of relationship between turbid-phlegm and hyperlipidaemia,” Clinical Journal of Traditional Chinese Medicine, vol. 16, no. 3, pp. 201–202, 2004. View at Google Scholar
  185. Q. F. Xian, Y. Liu, W. Zou, and J. Wang, “Research progress of Chinese medicine treatment of HAART-related hyperlipidemia,” Chinese Journal of Chinese Materia Medica, vol. 38, no. 15, pp. 2530–2533, 2013. View at Google Scholar
  186. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, “Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III),” Journal of the American Medical Association, vol. 285, no. 19, pp. 2486–2497, 2001. View at Google Scholar · View at Scopus
  187. T. A. Jacobson, M. Miller, and E. J. Schaefer, “Hypertriglyceridemia and cardiovascular risk reduction,” Clinical Therapeutics, vol. 29, no. 5, pp. 763–777, 2007. View at Publisher · View at Google Scholar · View at Scopus
  188. M. J. Wilkinson, L. J. Laffin, and M. H. Davidson, “Overcoming toxicity and side-effects of lipid-lowering therapies,” Best Practice & Research Clinical Endocrinology & Metabolism, vol. 28, no. 3, pp. 439–452, 2014. View at Google Scholar
  189. C. R. Harper and T. A. Jacobson, “The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis,” Current Opinion in Lipidology, vol. 18, no. 4, pp. 401–408, 2007. View at Publisher · View at Google Scholar · View at Scopus
  190. E. Bruckert, G. Hayem, S. Dejager, C. Yau, and B. Bégaud, “Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study,” Cardiovascular Drugs and Therapy, vol. 19, no. 6, pp. 403–414, 2005. View at Publisher · View at Google Scholar · View at Scopus
  191. S. Wang, Y. Hu, W. Tan et al., “Compatibility art of traditional Chinese medicine: from the perspective of herb pairs,” Journal of Ethnopharmacology, vol. 143, no. 2, pp. 412–423, 2012. View at Publisher · View at Google Scholar · View at Scopus
  192. X. Liu, W. Y. Wu, B. H. Jiang, M. Yang, and D. A. Guo, “Pharmacological tools for the development of traditional Chinese medicine,” Trends in Pharmacological Sciences, vol. 34, no. 11, pp. 620–628, 2013. View at Google Scholar
  193. H. Feng, W. Chen, and C. Zhu, “Pharmacokinetics study of bio-adhesive tablet of Panax notoginseng saponins,” International Archives of Medicine, vol. 4, no. 1, article 18, 2011. View at Publisher · View at Google Scholar · View at Scopus
  194. X. Y. Guo, J. Liu, J. Liu et al., “Use of traditional Chinese medicine in Chinese patients with coronary heart disease,” Biomedical and Environmental Sciences, vol. 26, no. 4, pp. 303–310, 2013. View at Google Scholar
  195. A. Dasgupta, “Effect of herbal remedies on clinical laboratory tests,” in Accurate Results in the Clinical Laboratory, A. Dasgupta and J. L. Sepulveda, Eds., Chapter 7, pp. 75–92, Elsevier, San Diego, Calif, USA, 2013. View at Google Scholar
  196. K. L. Miller, R. S. Liebowitz, and L. K. Newby, “Complementary and alternative medicine in cardiovascular disease: a review of biologically based approaches,” American Heart Journal, vol. 147, no. 3, pp. 401–411, 2004. View at Publisher · View at Google Scholar · View at Scopus
  197. M. L. Kashyap, M. E. McGovern, K. Berra et al., “Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia,” The American Journal of Cardiology, vol. 89, no. 6, pp. 672–678, 2002. View at Publisher · View at Google Scholar · View at Scopus
  198. E. Chan, M. Tan, J. Xin, S. Sudarsanam, and D. E. Johnson, “Interactions between traditional Chinese medicines and Western therapeutics,” Current Opinion in Drug Discovery and Development, vol. 13, no. 1, pp. 50–65, 2010. View at Google Scholar · View at Scopus
  199. H. Wu, J. Bei, and J. Guo, “Chinese herbal medicine for treatment of dislipidemia,” Journal of Geriatric Cardiology, vol. 6, no. 2, pp. 119–125, 2009. View at Google Scholar · View at Scopus
  200. J. C. Li, X. Y. Cheng, J. Gu, and R. Tan, “The effects of Gegen-Danshen prescription on the lipid metabolism in hyperlipidemia rats,” Journal of Southwest University for Nationalities: Natural Science Edition, vol. 36, no. 6, pp. 926–924, 2012. View at Google Scholar